Author: healthadmin

Italy’s Angelini Pharma has set its sights on the lucrative U.S. market, buying rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster Firdapse for $4.1 billion. Rome-based Angelini, a privately held family-owned company founded in 1919, is paying $31.50 per share for Florida-based Catalyst. This represents a 3% premium to Catalyst’s stock price at yesterday’s closing price and a 21% premium to its stock price on April 22, before market activity made it publicly known that a sale was imminent. Bloomberg reported on the possible acquisition on April 27th, causing the stock price to soar even further. The companies expect…

A survey of more than 7,000 people in Australia, the UK and the US found that 3.2% of the population reported engaging in the creation, sharing and/or threat of sharing sexual deepfakes. Men, young adults, non-white respondents, and people with disabilities were more likely to engage in this behavior. 18% of people viewed these images intentionally, mostly out of curiosity. This study Computers in human behavior. Sexual deepfakes are synthetic sexual images, videos, or audio recordings created or altered using AI or other digital tools. These are usually created to make it appear as if a real person is naked,…

When Optimi Health launched its 2.5 million-share initial public offering (IPO) last month (PDF), the timing couldn’t have been better for the Vancouver-based maker of psychedelic drugs. President Donald Trump recently signed an executive order accelerating research and loosening regulations on psychedelic drugs, reportedly at the urging of podcast mogul Joe Rogan, sparking an unprecedented conversation about the potential of psychedelic drugs to treat mental illness. And it’s the perfect time for early entrants like Canada’s Optimi to attract investors. “Donald Trump, who is, for better or worse, the most popular person in the world, and probably the second most…

Following the surprise rejection in early 2026, the FDA agreed to reconsider the T-cell therapy based on the same single-arm trials it had previously found problematic. For Pierre Fabre Pharmaceuticals and Atala Biotherapeutics’ Evalo, the FDA agreed in a recent meeting that a single-arm study with appropriate historical controls “may serve as an appropriate, well-controlled study” to support a regulatory filing, the companies announced Thursday. Pierre Fabre and Atala aim to get Evalo, also known as Tabelleklucel or Tabcel, approved for patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+PTLD) who have failed anti-CD20 therapy. Before the FDA,…

In this interview, news medical talk to Dr. Katie BarberAbout , Clinical Director, General Practitioner, Registered BMS Menopause Specialist, Oxford Menporest menopausethe influence of Vasomotor symptomsthe role of non-hormonal therapy like fesoline tanto Contribute to improving patient care. Image credit: Pixel-Shot/Shutterstock.com Hot flashes and night sweats are often dismissed as a normal part of menopause. What do people misunderstand about these symptoms, and how can effective treatment change patients’ daily lives? One of the biggest misconceptions is that hot flashes (vasomotor symptoms) and night sweats are just “uncomfortable” and don’t significantly impact your daily life. In fact, for approximately 25-30%…

Recent research published in journals Personality and Social Psychology Bulletin Evidence shows that how single people think about their relationships is related to how happy they are single. Scientists have found that single people who expect high levels of intimacy in relationships are more likely to seek out partners and ultimately have satisfying relationships. On the other hand, expecting negative relationship experiences tends to lead people to remain single, suggesting that an individual’s image of partnership has a significant impact on their romantic future. Being single is becoming an increasingly popular lifestyle choice around the world. As a result, scientists…

GLP-1 drugs such as Ozempic have transformed treatment for many people with type 2 diabetes by lowering blood sugar levels and supporting weight loss. However, researchers are finding that these drugs do not work equally well for everyone. A new study from Japan suggests that a person’s eating habits and the reasons behind overeating may play a big role in the long-term effects of these drugs. Scientists followed 92 diabetic patients during the first year of treatment with a GLP-1 receptor agonist. The results showed that people who tended to overeat because the food looked or smelled appealing were more…

Medicare Advantage now covers more than half of beneficiaries, but federal enforcement, mostly with relatively small penalties, may not be enough to ensure accountability across the rapidly expanding system, a new study finds. Study: Federal Enforcement Action Against Medicare Advantage Plans. Image credit: dailyplus/Shutterstock.com Recent research published in JAMA Internal Medicine Highlights opportunities to strengthen federal enforcement of private Medicare plans. The researchers analyzed enforcement actions in more than 1,100 contracts over 10 years and found that penalties vary from year to year and remain relatively modest. Approximately 42% of contracts Cited at least once, Questions have been raised about…

While GLP-1 drugs are revolutionizing obesity treatment, new research reveals a surprising reality. People can face stigma whether they lose weight, gain it back, or don’t lose weight at all. Research: An experimental study of the use and discontinuation of GLP-1 receptor agonists to blame for weight loss and recovery. Image credit: KaterynaBorodina/Shutterstock.com In a recent study published in International Journal of ObesityA group of researchers investigated whether people experience stigma after losing or regaining weight after using and discontinuing glucagon-like peptide-1 receptor agonist (GLP-1RA) drugs. Public attitudes toward GLP-1 weight loss remain divided Weight loss drugs such as GLP-1RA…

WASHINGTON (AP) – The Trump administration will soon propose loosening Biden-era limits on “permanent chemicals” in drinking water, deferring stricter standards for two common types and eliminating limits on some rarer forms, according to Environmental Protection Agency officials.The proposal begins the first-ever formal process to roll back parts. Restrictions on PFAS in drinking water It was finalized during former President Joe Biden’s administration. Authorities at the time found they increased the risk of cardiovascular disease, certain cancers, and low birth weight babies.Jessica Cramer, director of the Environmental Protection Agency’s Office of Water, said Thursday at a conference in Washington, D.C.,…